SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Hagglund H) "

Sökning: WFRF:(Hagglund H)

Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Johansson, J-E, et al. (författare)
  • Allogeneic haematopoietic stem-cell transplantation with reduced intensity conditioning for advanced stage Hodgkin's lymphoma in Sweden: high incidence of post transplant lymphoproliferative disorder
  • 2011
  • Ingår i: Bone Marrow Transplantation. - : Nature Publishing Group. - 1476-5365 .- 0268-3369. ; 46:6, s. 870-875
  • Tidskriftsartikel (refereegranskat)abstract
    • Allogeneic transplantation after reduced intensity conditioning (allo-RIC) is a treatment option for patients with Hodgkin's lymphoma (HL) relapsing after autologous transplantation. In all, 23 adult patients with HL underwent allo-RIC in Sweden between 2000 and 2007. The median number of previous treatment lines was five and 20 patients (87%) were previously autografted. TRM at 100 days and at 1 year was 13 and 22% respectively. Acute GVHD grades II-IV developed in 7 out of 23 patients (30%) and chronic GVHD in 10 out of 20 patients at risk (50%). The OS and EFS at three years was 59 and 27%, respectively. Four patients (17%) developed post transplant lymphoproliferative disease (PTLD) after a median time of 55 days (range 38-95); two of these patients later died. The study confirmed that allo-RIC is feasible, but associated with a substantial relapse rate: only 20% of the patients were still alive 7 years after the transplant. A finding of high incidence of PTLD needs to be confirmed in a larger trial that includes patients with non-HL and CLL. Bone Marrow Transplantation (2011) 46, 870-875; doi: 10.1038/bmt.2010.238; published online 18 October 2010
  •  
2.
  • Hulegardh, E., et al. (författare)
  • Outcome after HSCT in Philadelphia chromosome positive acute lymphoblastic leukemia in Sweden: a population-based study
  • 2014
  • Ingår i: Medical Oncology. - : Humana Press. - 1559-131X .- 1357-0560. ; 31:8, s. 66-66
  • Tidskriftsartikel (refereegranskat)abstract
    • Even in the tyrosine kinase inhibitor era, allogeneic hematopoietic stem cell transplantation (HSCT) is regarded as standard care for adult Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL). In this retrospective national study, we have reviewed the outcome after HSCT in Sweden for adult Ph-positive ALL between 2000 and 2009. In total, 51 patients with median age 42 (range 20-66) years underwent HSCT. Mainly allogeneic HSCT was performed (24 related donor, 24 unrelated donor and one cord blood), and only two patients were treated with an autologous HSCT. The 5-year OS was 51 (37-64) %. The probabilities of morphological relapse and non-relapse mortality (NRM) at 5 years were 36 (23-49) and 18 (9-29) %, respectively. For the allogeneic transplanted, the 5-year OS was for patients <40 years 70 (50-90) % and for patients >= 40 years 34 (16-52) %, p = 0.002. The 5-year probability of NRM was for patients <40 years 10 (2-28) % compared to 25 (11-42) % for patients >= 40 years (p = 0.04). Patients with chronic graft-versus-host disease (GVHD) had a 5-year morphological relapse probability of 20 (6-40) % compared to 59 (35-77) % for patients without chronic GVHD (p = 0.03). Age >= 40 years and the absence of chronic GVHD were confirmed as independent negative prognostic factors for relapse and non-relapse mortality in a multivariate analysis although the impact of chronic GVHD was significant only in the older age cohort.
  •  
3.
  • Press, R, et al. (författare)
  • Autologous haematopoietic stem cell transplantation: a viable treatment option for CIDP
  • 2014
  • Ingår i: Journal of Neurology, Neurosurgery and Psychiatry. - 0022-3050 .- 1468-330X. ; 85:6, s. 618-624
  • Tidskriftsartikel (refereegranskat)abstract
    • OBJECTIVE: Only 70-80% of patients with chronic inflammatory demyelinating polyneuropathy (CIDP) respond satisfactorily to the established first-line immunomodulatory treatments. Autologous haematopoietic stem cell transplantation (AHSCT) has been performed as a last treatment resort in a few therapy-refractory cases with CIDP. We describe the results of AHSCT in 11 consecutive Swedish patients with therapy-refractory CIDP with a median follow-up time of 28 months. METHOD: Case data were gathered retrospectively for AHSCT treatments in 11 patients with CIDP refractory to the first-line immunomodulatory treatments, intravenous high-dose immunoglobulin, corticosteroids and plasma exchange and to one or more second-line treatments used in 10 of the 11 patients. RESULTS: The median Inflammatory Neuropathy Cause and Treatment (INCAT) score within 1 month prior to AHSCT was 6 and the Rankin score 4. Total INCAT and Rankin scores improved significantly within 2-6 months after AHSCT and continued to do so at last follow-up. The motor action potential amplitudes (CMAP) improved already within 4 months (median) after AHSCT. Three of the 11 patients relapsed during the follow-up period, requiring retransplantation with AHSCT in one. Eight of the 11 patients maintained drug-free remission upon last follow-up. AHSCT was safe but on the short term associated with a risk of cytomegalovirus (CMV) and Epstein-Barr virus reactivation, CMV disease, haemorrhagic cystitis and pancreatitis. CONCLUSIONS: Our results though hampered by the limited number of patients and the lack of a control group suggest AHSCT to be efficacious in therapy-refractory CIDP, with a manageable complication profile. Confirmation of these results is necessary through randomised controlled trials.
  •  
4.
  •  
5.
  • Nahi, Hareth, et al. (författare)
  • An investigation into whether deletions in 9p reflect prognosis in adult precursor B-cell acute lymphoblastic leukemia : a multi-center study of 381 patients
  • 2008
  • Ingår i: Haematologica. - Pavia : Ferrata Storti Foundation. - 1592-8721 .- 0390-6078. ; 93:11, s. 8-1734
  • Tidskriftsartikel (refereegranskat)abstract
    • In acute lymphoblastic leukemia, besides age and white cell count at diagnosis, the cytogenetic abnormalities t(9;22)/BCR-ABL and t(4;11)/MLL-AF4 are important prognostic markers and are often included in the treatment stratification of patients with adult acute lymphoblastic leukemia. Deletions in 9p are seen in about 9% of cases of adult acute lymphoblastic leukemia, but their prognostic impact has been controversial. Cytogenetic data from 381 patients diagnosed with B-precursor acute lymphoblastic leukemia were reviewed. Chromosomal analysis was successful in 240 cases. Of these cases, 18 (8%) had abnormalities in 9p and they were compared with patients with normal karyotypes and patients with t(9;22)/BCR-ABL. Patients with abnormalities of chromosome 9 showed significantly shorter overall survival compared with patients with normal karyotypes. In fact, overall survival was similar to that in the poor prognosis t(9;22)/BCR-ABL-positive group. Our data suggest that chromosomal abnormalities involving 9p may have a significant negative impact on survival in adult B-precursor acute lymphoblastic leukemia.
  •  
6.
  •  
7.
  •  
8.
  •  
9.
  • Hallböök, Helene, et al. (författare)
  • Autologous and allogeneic stem cell transplantation in adult ALL : The Swedish Adult ALL Group experience
  • 2005
  • Ingår i: Bone Marrow Transplantation. - London : Nature Publishing Group. - 0268-3369 .- 1476-5365. ; 35:12, s. 1141-1148
  • Tidskriftsartikel (refereegranskat)abstract
    • Adult patients with acute lymphoblastic leukaemia (ALL) have been treated according to national protocols in Sweden since 1986. Stem cell transplantation (SCT) has been recommended in first remission for patients with risk factors for relapse, and for standard risk patients only after relapse. In this retrospective study, the results of autologous and allogeneic SCT in these populations were evaluated. In total, 187 patients with a median age of 34 years (17-66 years) underwent SCT. The 5-year disease-free survival (DFS), for all patients, was 26% (Confidence intervals (CI) 20-32%). The 5-year DFS was higher for patients transplanted in first remission 32% (CI 24-40%) compared to 14% (CI 5-23%; P<0.0001) in patients transplanted beyond first remission. No significant differences in DFS (P=0.06) were determined between autologous, related donor and unrelated donor SCT in the whole cohort. A lower relapse rate was counterbalanced by higher treatment-related mortality in patients undergoing allogeneic SCT. In Philadelphia-positive ALL, allogeneic SCT was superior to autologous SCT, with a 5-year DFS of 30% (CI 12-47%) vs 0% (P=0.04). Limited chronic graft-versus-host-disease (GVHD) was associated with an improved DFS of 53% (CI 38-69%) compared to no chronic GVHD of 22% (CI 10-36%; P=0.0008), indicating a clinically important graft-versus-leukaemia effect.
  •  
10.
  •  
Skapa referenser, mejla, bekava och länka
Typ av publikation
tidskriftsartikel (142)
konferensbidrag (55)
forskningsöversikt (3)
Typ av innehåll
refereegranskat (134)
övrigt vetenskapligt (66)
Författare/redaktör
Hagglund, H (178)
Ringden, O (75)
Remberger, M. (73)
Ljungman, P (61)
Hägglund, Hans (57)
Mattsson, J. (33)
visa fler...
Machaczka, M (27)
Aschan, J (25)
Lonnqvist, B (23)
Hallbook, H. (23)
Winiarski, J (21)
Kimby, E (19)
Sander, B (19)
Nilsson, G (18)
Wahlin, A (17)
Sparrelid, E (17)
Gulen, T (17)
Le Blanc, K (14)
Hagglund, M. (14)
Carlens, S (14)
Hallböök, Helene (14)
Juliusson, G (12)
Karlsson, K (11)
Johansson, JE (11)
Hagglund, Hans (11)
Nilsson, Gunnar (11)
Klimkowska, M (11)
Hassan, M (10)
Dahlen, B (10)
Malm, C. (9)
Remberger, Mats (9)
Astrom, M. (9)
Wahlin, Anders (9)
Hassan, Z. (8)
Johansson, Jan-Erik (8)
Afram, G. (8)
Hägglund, H (8)
Klaesson, S (8)
Smedmyr, B. (8)
Persson, H (7)
Uhlin, M. (7)
Nahi, H (7)
Omazic, B (7)
Juliusson, Gunnar (7)
Hagerman, I (7)
Kumlien, G (7)
Hulegardh, E. (7)
Wahlin, BE (7)
Sander, Birgitta (7)
Kimby, Eva (7)
visa färre...
Lärosäte
Karolinska Institutet (162)
Uppsala universitet (63)
Linköpings universitet (19)
Umeå universitet (12)
Lunds universitet (10)
Göteborgs universitet (5)
visa fler...
Röda Korsets Högskola (3)
Örebro universitet (2)
Högskolan i Skövde (2)
Kungliga Tekniska Högskolan (1)
Stockholms universitet (1)
Linnéuniversitetet (1)
visa färre...
Språk
Engelska (200)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (75)
Naturvetenskap (5)
Samhällsvetenskap (1)
Humaniora (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy